Delandistrogene Moxeparvovec: Micro-Dystrophin Gene Therapy and Pharmacovigilance

Delandistrogene moxeparvovec is a single-infusion gene therapy developed for Duchenne muscular dystrophy (DMD). It uses an adeno-associated virus serotype rh74 (AAVrh74) vector to deliver a shortened, engineered dystrophin gene to muscle cells. The therapeutic aim is to make a micro-dystrophin protein that provides some of the structural support normally supplied by full-length dystrophin.

The treatment is unusual from a pharmacovigilance perspective: administration is brief, but the intended biological effect may persist. The vector cannot be withdrawn after infusion, repeat dosing is not recommended, and some safety events emerge during the weeks or months after treatment. Safe use therefore depends on patient selection, immunosuppression, laboratory surveillance, rapid clinical escalation and long-term record linkage.

This article follows the product from its scientific origins to the current United States label and European Union regulatory outcome. It distinguishes evidence from regulatory decisions and does not treat a company statement, an uncontrolled comparison or a regulatory authorisation as proof of established clinical benefit.

Duchenne Muscular Dystrophy and the Therapeutic Rationale

DMD is an X-linked disorder caused by pathogenic variants in the DMD gene. In affected boys, absent or deficient dystrophin destabilises the muscle-fibre membrane during contraction. Progressive muscle injury leads to loss of motor function and, later, respiratory and cardiac complications.

Dystrophin is a very large protein, and its coding sequence exceeds the carrying capacity of commonly used AAV vectors. The programme therefore uses a compact micro-dystrophin construct: a deliberately shortened version that retains selected functional regions and is intended to associate with the muscle-fibre membrane. It is not full-length dystrophin, and expression of the engineered protein does not by itself establish the magnitude or durability of clinical benefit.

This distinction matters in safety assessment. The product introduces a viral vector and a non-native protein to multiple muscle tissues, while the patient’s underlying disease already affects skeletal, respiratory and cardiac muscle. Biomarker change, disease progression and treatment-emergent toxicity must therefore be interpreted together.

Classification and Molecular Design

The current US prescribing information specifies an AAVrh74 vector, baseline anti-AAVrh74 antibody testing, and a single intravenous dose. It also excludes patients with any deletion in exon 8 and/or exon 9 because of the risk of severe immune-mediated myositis. These product-specific conditions are part of the safety architecture, not administrative details.[1]

Scientific and Development Origins

The programme emerged from work at the Center for Gene Therapy at Nationwide Children's Hospital in Columbus, Ohio. Investigators developed an AAVrh74 vector carrying a micro-dystrophin cassette under the MHCK7 promoter, combining muscle-directed expression with a systemically administered vector. The first human study enrolled a small group of ambulatory boys and provided early evidence of transgene expression; the investigators themselves emphasised the need for confirmation in a randomised trial.[8]

Sarepta Therapeutics licensed the programme from Nationwide Children's in 2018 and assumed commercial development. In December 2019, Sarepta and Roche entered a licensing and collaboration arrangement that gave Roche rights to develop, manufacture and commercialise SRP-9001 outside the United States. The agreement is relevant to the product's international development and commercial history, but it does not alter the safety responsibilities of the relevant marketing authorisation holder in a particular jurisdiction.[13]

The first-in-human programme began before the collaboration. Subsequent studies evaluated dose, expression, motor-function measures and safety in larger cohorts. The product received US orphan-drug and fast-track designations during development. These designations describe regulatory development status; they should not be presented as independent evidence of efficacy.[2]

Clinical Programme and Interpretation of Efficacy Evidence

Early open-label studies reported micro-dystrophin expression and changes in motor-function measures. Their small size, lack of concurrent controls in some cohorts, and the natural variability of DMD progression limited the conclusions that could be drawn. The phase 1/2a programme was important for dose and biological plausibility, but it could not establish comparative clinical benefit on its own.[8]

The phase 2 Study 102 enrolled 41 ambulatory boys aged 4 to under 8 years in a double-blind, placebo-controlled study with a later crossover. Its biological endpoint—micro-dystrophin expression at week 12—was met. The other primary endpoint, change in NSAA at week 48, was not statistically significant in the full randomised population (least-squares mean change 1.7 points with treatment versus 0.9 with placebo; p=0.37). Baseline functional imbalance complicated interpretation of subgroup findings, which remain exploratory.[2,9]

The phase 3 EMBARK trial randomised 125 ambulatory boys aged 4 to under 8 years to a single infusion of delandistrogene moxeparvovec or placebo, followed by a crossover period. At week 52, the primary endpoint, change in North Star Ambulatory Assessment (NSAA) total score, was not statistically significant: the between-group difference was 0.65 points (95% confidence interval −0.45 to 1.74; p=0.2441). Several secondary timed-function measures favoured treatment, but their interpretation must retain the hierarchy of endpoints and the prespecified analysis plan. A favourable secondary result does not turn a missed primary endpoint into a positive primary result.[10]

At the two-year report, after crossover and continued follow-up, analyses compared treated participants with external controls. The authors reported later functional differences, but after crossover there was no longer a concurrent randomised untreated group for the full follow-up. These data contribute to the evolving evidence base; they should be described with the design limitation visible.[11]

Regulatory Lifecycle

The 2023 FDA review records a difficult evidentiary decision. Reviewers considered whether micro-dystrophin expression was a surrogate reasonably likely to predict clinical benefit and documented limitations in the clinical correlation. FDA nevertheless granted accelerated approval for the narrowly defined ambulatory population. The later EMBARK result failed its primary endpoint, while the 2024 FDA decision relied on the totality of evidence to grant traditional approval for ambulatory patients and accelerated approval for non-ambulatory patients. These are regulatory decisions made on the evidence submitted at the time; they do not erase the uncertainty recorded in the underlying trial and review materials.[2,3,10]

The European assessment reached a different outcome. The CHMP recommended refusal after concluding that efficacy had not been convincingly demonstrated and that uncertainty remained about whether the observed micro-dystrophin expression translated into meaningful clinical benefit. The European Commission issued the final refusal. A refusal is not a safety withdrawal: it means no EU marketing authorisation was granted following that application.[6,7]

In November 2025, FDA approved a boxed warning for acute serious liver injury and acute liver failure, including fatal outcomes, and restricted the US indication to ambulatory patients aged 4 years and older with a confirmed DMD mutation. The FDA also required a prospective observational postmarketing study in at least 200 treated patients with at least 12 months of follow-up because spontaneous reporting alone was insufficient to assess the risk.[4,5]

As of the current US prescribing information revised in August 2026, delandistrogene moxeparvovec remains indicated only for ambulatory patients aged 4 years or older, with contraindication for specified DMD gene deletions and limitations of use for certain hepatic conditions, recent vaccination and active or recent infection. No EU marketing authorisation was granted.[1,6]

Safety Profile and Important Risks

The product's safety profile combines acute vector-related immune effects, hepatic injury, cardiac events, genotype-specific myositis and the background complications of DMD. A case narrative should not collapse these different mechanisms into a generic adverse-event label.

Acute serious liver injury and liver failure

Elevations in liver enzymes are common after treatment and usually begin within eight weeks. In clinical studies, most reported laboratory abnormalities were asymptomatic and resolved spontaneously or with systemic corticosteroids. The current label also describes acute serious liver injury and acute liver failure, including fatal outcomes in non-ambulatory patients in clinical and postmarketing settings. A serious non-fatal case included mesenteric vein thrombosis, bowel ischaemia and necrosis, and portal hypertension following liver injury.[1]

The 2025 fatal reports changed the regulatory risk picture. FDA added a boxed warning, narrowed the authorised US population and required a postmarketing study. The reports should be described as serious safety evidence prompting action; spontaneous reports alone do not estimate incidence or prove that all liver injury follows the same mechanism.

Patients with pre-existing liver impairment, chronic hepatic conditions or acute liver disease may be at higher risk. The current label does not recommend treatment in patients with defined pre-existing liver impairment or active hepatic viral infection. Baseline hepatic status and post-infusion trends are therefore central to both clinical risk management and pharmacovigilance case interpretation.[1,4]

Myocarditis and cardiac injury

Myocarditis and troponin-I elevations have been observed, including serious cases. The current label calls for a baseline troponin-I measurement and weekly monitoring during the first month, with continued assessment if clinically indicated. Because DMD itself can cause cardiomyopathy, the record should distinguish pre-existing cardiac disease, temporal changes after infusion, symptoms, biomarkers, imaging, concomitant treatment and clinical adjudication.[1]

Immune-mediated myositis and genotype

Severe or life-threatening immune-mediated myositis has been reported in patients with specified deletions affecting portions of exons 1–17 and/or exons 59–71. The product is contraindicated in patients with any deletion in exon 8 and/or exon 9. New muscle pain, tenderness, weakness or functional decline must be interpreted against baseline DMD progression and the patient's exact genotype. Failure to preserve genetic eligibility data can undermine both clinical decisions and signal review.[1]

Infusion reactions, infection and other observed reactions

Infusion-related hypersensitivity, including anaphylaxis, can occur during administration. The label requires observation during infusion and for at least three hours afterward. Corticosteroids and, where needed, additional immunosuppressive treatment may increase susceptibility to serious infection. Other common reactions in the pooled clinical safety population included vomiting, nausea, liver injury, pyrexia, thrombocytopenia and increased troponin-I. Rates from clinical trials should not be treated as postmarketing incidence estimates.[1]

Vector immunity, eligibility and inability to redose

The label requires anti-AAVrh74 antibody testing before treatment and does not recommend administration at or above the specified antibody threshold. Following infusion, patients develop anti-AAVrh74 antibodies. The current label says not to re-administer the product. As a result, initial eligibility, vector lot and dose, infusion details, corticosteroid exposure, immune response and long-term outcomes should remain linkable in the safety record.[1]

Pharmacovigilance Questions Across the Treatment Lifecycle

A single administration does not mean a single exposure record. A practical safety assessment should connect:

• Before infusion: confirmed DMD mutation and exon status; ambulatory status; hepatic and cardiac baseline; anti-AAVrh74 result; recent infection or vaccination; prior therapies; and corticosteroid regimen.
• At infusion: dose, vector lot, infusion start and end times, infusion reactions, concomitant immunomodulation and any administration deviation.
• Early follow-up: liver tests, platelet counts, troponin-I, symptoms, specialist assessments, infection and treatment response.
• Longitudinal follow-up: functional trajectory, cardiac and respiratory status, immune-mediated events, hospitalisations, concomitant treatment, survival and any change in disease stage.
• Outcome interpretation: distinguish treatment-emergent changes from expected DMD progression, concurrent infection, pre-existing organ disease, corticosteroid effects and measurement variability.

These are recommended operational data elements for meaningful product-level assessment, not a replacement for the current jurisdiction-specific label or applicable legal reporting rules.

Benefit-Risk Assessment and QPPV Oversight

For a one-time gene therapy, the treatment date is only the start of the safety follow-up. A pharmacovigilance system should preserve a durable link between patient, product, vector lot, eligibility assessment, infusion, laboratory results, clinical events and long-term outcomes. Where information is received through a treating centre, registry, company programme or partner, procedures should make source, awareness date, follow-up and reconciliation traceable.

Aggregate analyses should use denominators that reflect the treated population and should separate ambulatory and non-ambulatory patients, age, baseline hepatic status, genotype, dose, clinical-trial versus postmarketing exposure, and relevant follow-up duration. A clustering of liver injury after treatment may support signal evaluation, but spontaneous-report counts cannot by themselves establish incidence. Case-level review should distinguish asymptomatic enzyme changes from acute clinical liver injury, impending failure, fatal outcome and complications such as thrombosis or portal hypertension.

The known risk-management measures also need effectiveness review. Relevant evidence includes completion and timeliness of weekly liver monitoring, detection-to-escalation intervals, specialist consultation where serious injury is suspected, corticosteroid adherence, access to an appropriate healthcare facility during the labelled period, and resolution of laboratory abnormalities. Such measures are prudent oversight indicators; they should not be presented as separate legal mandates unless a binding requirement or approved product document says so.

The product's benefit-risk profile remains jurisdiction-specific and evidence-sensitive. The US label reflects FDA's authorisation for a defined ambulatory population with prominent liver-risk controls. The EU refusal reflects the outcome of a separate assessment of the submitted evidence. A QPPV or safety lead should preserve both facts without implying that one regulator's action automatically determines another jurisdiction's decision.

Common Pharmacovigilance Failure Modes

Illustrative system weaknesses include:

• coding a marked liver-test increase without determining whether clinical liver injury or impaired synthetic function developed;
• closing follow-up after the expected early monitoring window despite ongoing symptoms or abnormal results;
• failing to capture ambulatory status, exon-level genotype or pre-existing hepatic disease;
• treating micro-dystrophin expression or an uncontrolled external-control comparison as an established patient-level clinical benefit;
• combining cases from different AAVrh74 products without distinguishing active substances, transgenes and indications;
• interpreting the EU refusal as a safety withdrawal or the US label restriction as proof that risk is confined to non-ambulatory patients;
• losing product, lot or infusion traceability because the therapy was administered once and later care moved to another provider.

The QPPV should ensure that new evidence is assessed through the established signal-management and benefit-risk process, with appropriate escalation, documentation, partner oversight and regulatory communication under the applicable local framework.

Practical Review Checklist

• Is the active substance and exact gene-therapy product identified?
• Are the infusion date, dose, lot, site and administration record available?
• Are mutation details, exon status, ambulatory status and baseline hepatic/cardiac conditions documented?
• Are anti-AAVrh74 test results, recent infection/vaccination and corticosteroid exposure captured?
• Are liver function, platelet and troponin-I results linked to clinical signs, treatment and outcome?
• Are serious liver injury, liver failure, myocarditis, myositis and infusion reactions assessed as distinct clinical events?
• Are follow-up attempts, source documents, awareness date and regulatory reporting decisions traceable?
• Do aggregate reviews distinguish trial from postmarketing cases and preserve meaningful denominators?
• Are current jurisdictional labels and the EU refusal accurately represented?
• Are postmarketing study progress and risk-control effectiveness reviewed using verified data?

Key Takeaways

Delandistrogene moxeparvovec is an AAVrh74 gene-transfer therapy intended to produce micro-dystrophin after one intravenous infusion. Its scientific rationale and early expression data did not remove uncertainty about the relationship between surrogate expression and clinical benefit.

EMBARK did not meet its week-52 primary endpoint. FDA's US regulatory decisions, the EMA's final refusal and the postmarketing liver-safety actions must be described as distinct evidence-based jurisdictional outcomes.

The 2025 FDA boxed warning and ambulatory-only indication make acute liver injury and liver failure central to current US risk management. Pharmacovigilance must extend beyond the infusion through linked monitoring, rapid escalation and durable follow-up.

References

1. U.S. Food and Drug Administration. ELEVIDYS (delandistrogene moxeparvovec-rokl) current prescribing information, DailyMed; revised August 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3525abcd-fbd2-46c5-9706-cffdf2e8a361
2. U.S. Food and Drug Administration. Summary Basis for Regulatory Action: ELEVIDYS, 21 June 2023. https://www.fda.gov/media/169746/download
3. U.S. Food and Drug Administration. FDA expands approval of gene therapy for patients with Duchenne muscular dystrophy, 20 June 2024. https://www.fda.gov/news-events/press-announcements/fda-expands-approval-gene-therapy-patients-duchenne-muscular-dystrophy
4. U.S. Food and Drug Administration. FDA takes action on new boxed warning for acute serious liver injury and acute liver failure following treatment with Elevidys, 14 November 2025. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-takes-action-new-boxed-warning-acute-serious-liver-injury-and-acute-liver-failure-following
5. U.S. Food and Drug Administration. Approval letter for ELEVIDYS, 14 November 2025, including postmarketing requirement under section 505(o). https://www.fda.gov/media/189632/download
6. European Medicines Agency. Elevidys: European Public Assessment Report and refusal of marketing authorisation, final decision 24 September 2025. https://www.ema.europa.eu/en/medicines/human/EPAR/elevidys
7. European Medicines Agency. Questions and answers on refusal of marketing authorisation for Elevidys. https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-elevidys-delandistrogene-moxeparvovec_en.pdf
8. Mendell JR, Sahenk Z, Lehman K, et al. Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial. JAMA Neurology. 2020;77(9):1122–1131. PMID: 32539076. https://pubmed.ncbi.nlm.nih.gov/32539076/
9. Mendell JR, et al. Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy. Phase 2 Study 102. PMID: 37497476. https://pubmed.ncbi.nlm.nih.gov/37497476/
10. Mendell JR, Shieh PB, McDonald CM, et al. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nature Medicine. 2025;31:2035–2051. PMID: 39385046. https://pubmed.ncbi.nlm.nih.gov/39385046/
11. McDonald CM, et al. Two-year outcomes following delandistrogene moxeparvovec treatment in ambulatory patients with Duchenne muscular dystrophy: phase 3 EMBARK trial. PMID: 41518520. https://pubmed.ncbi.nlm.nih.gov/41518520/
12. ClinicalTrials.gov. Study NCT03375164: A gene transfer therapy study to evaluate the safety of delandistrogene moxeparvovec (SRP-9001) in participants with Duchenne muscular dystrophy. https://clinicaltrials.gov/study/NCT03375164
13. Sarepta Therapeutics. Form 8-K and License, Collaboration, and Option Agreement with Roche, 21 December 2019. https://www.sec.gov/Archives/edgar/data/873303/000156459019046705/srpt-8k_20191221.htm
14. Nationwide Children's Hospital. FDA approval of gene therapy for Duchenne muscular dystrophy developed at Nationwide Children's Hospital, 22 June 2023. https://www.nationwidechildrens.org/newsroom/news-releases/2023/06/dmd_srp-9001
15. U.S. Food and Drug Administration. ELEVIDYS product page, approval history and current regulatory documents. https://www.fda.gov/vaccines-blood-biologics/tissue-tissue-products/elevidys

Regulatory Note

This article was checked against the US prescribing information revised in August 2026 and the EMA public assessment record available on 4 October 2026. Regulatory status and product information are jurisdiction-specific and may change. The article is educational and does not replace current prescribing information, applicable pharmacovigilance obligations or clinical judgement.